Videos | Coronavirus (COVID-19) | May 18, 2020

VIDEO: Overview of Hydroxychloroquine and FDA Warning in its use to Treat COVID-19

Marianne Pop, Pharm.D., BCPS, a clinical pharmacist and clinical assistant professor with the regional pharmacy program, University of Illinois at Chicago College of Pharmacy. She specializes in emergency medicine pharmacy as part of the regional pharmacy program at OSF Saint Anthony Medical Center in Rockford, Ill. In this interview she offers an overview of using hydroxychloroquine to treat COVID-19 (SARS-CoV-2) in relation to the recent FDA warning about its use causing increase cardiac issues, and data on its effectiveness to date.

Cardiology societies issued warnings soon after hydroxychloroquine started to be used as a treatment and the prevention of COVID-19. The drug has been used for decades to prevent malaria and to treat rheumatoid arthritis and lupus. However, some case reports indicate it can cause ECG QT-interval prolongation, which causes cardiac arrhythmias. Cardiologists say COVID also can cause myocarditis, which can initiate arrhythmias. Other drugs being used to treat COVID, such as azithromycin, also cause arrhythmias. These drugs combined with myocarditis can compound the arrhythmia issue, leading to serious adverse effects, including some patients deaths. This is what the FDA reported in a warning to clinicians in late April. 

However, there are numerous advocates that argue hydroxychloroquine needs to be used in less sick patients who are not already hypoxic to treat COVID and it is being used primarily in very sick patients where it is not effective. Advocates also argue the drug can be used to help prevent coronavirus, similar to the drug's effect in preventing malaria. In terms of drug safety, advocates argue the drug has been used in millions of patients for more than 50 years without a high risk of arrhythmias. Several trials are now underway in the United States to test its use against COVID-19, but enrollment has been hampered because of the FDA warning. There will likely be more interest in hydroxychloroquine after it was revealed May 18, 2020, that President Trump is taking the drug for prophylaxis against COVID-19.

 

Related Hydroxychloroquine Content:

FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine for COVID-19

COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues

VIDEO: Why QT-prolongation Occurs in COVID-19 Patients on Hydroxychloroquine — Interview with Andrew Krahn, M.D.

FDA Reports of Deaths and Injuries From Use of Antimalarial hydroxychloroquine in COVID-19 Patients

WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19

 

VIDEO: Cardiologists Manage Trial Testing if Hydroxychloroquine Protects Clinicians From COVID-19

First Large-scale U.S. Study on Hydroxychloroquine COVID-19 Prophylaxis Begins in Detroit

AHA, ACC, HRS Caution Use of COVID-19 Therapies Hydroxychloroquine and Azithromycin in Cardiac Patients

1810 Views

Recent Videos View all 642 items

Sponsored Videos View all 46 items

Cardiovascular Ultrasound | July 20, 2022

Enhanced features on the Philips EPIQ CVx ultrasound system provide a next level photorealistic 3D rendering, making it easy for users to interpret what they are seeing. The TrueVue feature enhances the sense of depth and space, producing images that appear natural and realistic to the human eye.  

Watch the video to check out how TrueVue can help improve views of LAA and MV morphology. 

Cardiovascular Ultrasound | July 07, 2022

Automated features on the Philips EPIQ CVx cardiology ultrasound system are helping to bring consistency and speed to every echo exam. The AI-empowered algorithm delivers fast and consistent measurements – in half the time of manual methods.*  

Watch the video to see how you can put “smart”  to work with the latest AI-powered quantification tools. 

*External study with external sonographers comparing the results of 18 exams with and without AutoMeasure

Cardiovascular Ultrasound | June 14, 2022

The X5-1c transducer from Philips provides enhanced clinical information in transthoracic imaging over a standard phased array transducer. When combined with nSIGHT Plus image formation on the EPIQ CVx cardiology ultrasound system, the X5-1c transducer enables image quality rarely seen from a transthoracic transducer. 

Watch the video to learn about the benefits which may include decreased exam time due to faster access to echo windows, increased confidence in quantification results and more. 

Cardiovascular Ultrasound | May 31, 2022

Philips recently announced an update to their flagship EPIQ CVx premium cardiology ultrasound system. Watch the video to learn about the latest features including the next-generation nSIGHT Plus imaging architecture system that leverages both hardware and software to support sophisticated image formation and enhanced image quality.

Conference Coverage View all 459 items

Cath Lab View all 316 items

Cardiac Imaging View all 286 items

Cardiac Diagnostics View all 78 items

EP Lab View all 83 items

Information Technology View all 168 items

Subscribe Now